What is the ticker symbol for Valeant Pharmaceuticals International?
Valeant Pharmaceuticals International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VRX." How do I buy shares of Valeant Pharmaceuticals International?
What happened to Valeant Pharmaceuticals?
Until the last few months, Valeant was one of the market's fastest-growing pharmaceutical companies, but its stock has since collapsed. After peaking at more than $260 a share in August of 2015, it is trading at about $34 a share as of Wednesday afternoon.
Should you buy Valeant Pharmaceuticals International (VRA) stock?
Wall Street analysts have given Valeant Pharmaceuticals International a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains.
Who is the CFO of Valeant Pharmaceuticals Inc?
Pearson joined Valeant in 2008, after 23 years at the management consulting company McKinsey. Schiller joined as CFO in 2011, after 24 years at Goldman Sachs. Given the company's epic demise, the financialization of pharmaceuticals is a strategy that doesn’t seem to be working out too well.
See more
What happened to Valeant Pharmaceuticals stock?
In the 2010s, Valeant went on an unsustainable acquisition spree that drove its share price from around $20 per share to as high as $263.81 in 2015 — but left the company buried under a mountain of debt.
Is Valeant publicly traded?
(formerly Valeant Pharmaceuticals International, Inc.) is a Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada....Bausch Health.TypePublicTraded asTSX: BHC S&P/TSX 60 componentISINCA0717341071IndustryPharmaceuticalsFounded1959 (as ICN Pharmaceuticals)13 more rows
Did Valeant go out of business?
Valeant will go by Bausch Health Companies, marking the company's second name change since 2010.
What was Valeant Pharmaceuticals stock symbol?
VRX(VRX) Stock Price, News, Quote & History - Yahoo Finance.
How much money did Bill Ackman lose on Valeant?
a $4 billionBill Ackman, CEO of Pershing Square Capital Management, has said sorry to shareholders. Hedge fund billionaire Bill Ackman, who rode out his stake in troubled Canadian pharmaceutical firm Valeant to a $4 billion loss, has delivered a long-awaited apology to investors.
Who shorted Valeant?
Quadir, who is 28, famously crossed swords with the famed hedge-fund manager Bill Ackman on the pharmaceutical company Valeant in 2015. She was short the stock and Ackman was long.
Why did Mike sue Valeant?
In 2017, Pearson sued Valeant Pharmaceuticals for $31 million as compensation for his alleged wrongful termination as CEO and chairman. In December 2017, a New Jersey judge ruled that Pearson should pursue his claim by arbitration rather than through the courts.
Did Valeant acquire Allergan?
William A. Ackman and Valeant Pharmaceuticals lost their hostile battle to buy Allergan and still came away with a total of $2.6 billion.
How did Valeant get caught?
Andrew Davenport and former Valeant executive Gary Tanner were accused by authorities of using secret shell companies, hidden email addresses and deceptive deals to get rich -- at the expense of investors at drug maker Valeant.
What products does Valeant Pharmaceuticals make?
Valeant Pharmaceuticals manufactures high quality skin cleansers, moisturizers, healing ointments and sunscreens. Valeant is always innovating with its product compositions looking to develop creative and ethical solutions CeraVe is a registered trademark of Valeant Pharmaceuticals.
What happened to Mike Pearson Valeant?
On April 13, 2016 it was announced that Pearson would be deposed from his position as CEO of Valeant on April 18, 2016. The removal was ordered by the Senate Special Committee on Aging who have been probing the soaring price of prescription drugs.
Who bought Biovail?
BiovailTypePublicFounded1991FounderEugene Melnyk Rolf Reininghaus Mahmood KhanDefunct2010FateMerged with Valeant Pharmaceuticals International16 more rows
Who are Valeant Pharmaceuticals International's key executives?
Valeant Pharmaceuticals International's management team includes the following people: Mr. Joseph C. Papa , CEO & Chairman (Age 63) Mr. Paul S....
Who are some of Valeant Pharmaceuticals International's key competitors?
Some companies that are related to Valeant Pharmaceuticals International include MERCK Kommanditgesellschaft auf Aktien (MRK) , Aphria (APHA) ,...
What other stocks do shareholders of Valeant Pharmaceuticals International own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Valeant Pharmaceuticals International investors own include...
What is Valeant Pharmaceuticals International's stock symbol?
Valeant Pharmaceuticals International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VRX."
How do I buy shares of Valeant Pharmaceuticals International?
Shares of VRX and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian...
How much money does Valeant Pharmaceuticals International make?
Valeant Pharmaceuticals International (TSE:VRX) has a market capitalization of C$0.00.
What is Valeant Pharmaceuticals International's official website?
The official website for Valeant Pharmaceuticals International is www.valeant.com .
How can I contact Valeant Pharmaceuticals International?
Valeant Pharmaceuticals International's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada . The specialty pharmaceutical comp...
Who is the CEO of Valeant?
Did Ackman lose Valeant?
As a result of these accounting issues coming to light, the company said Monday that it will replace CEO J. Michael Pearson. The company is looking for a new CEO, and Pearson will remain on board until they find one. Michael Pearson, the CEO of Valeant, will step down once the company finds a replacement.
Is Valeant a soap opera?
Ackman appears dangerously close to losing the entirety of his original $4.1 billion investment in Valeant, according to Matt Levine at Bloomberg View . Then there’s former CFO Howard Schiller.
Did Shkreli invent the orphan drug?
The Valeant story is so complicated and dramatic that one Wells Fargo analyst called it “ a soap opera “ in The New York Times. That almost seems too conservative a description for this story, so let’s dive in.
Is Valeant a platform company?
Shkreli didn’t invent that move. Valeant was doing it first. A report published by the House of Representatives in February showed that Valeant bought two “orphan drugs,” a term that describes medications used to treat rare diseases, in 2015 and hiked the prices by 525 percent and 212 percent respectively.
Does Valeant have a problem with accounting?
It’s not just a company that does research, then turns out prescription drugs. Instead , Valeant is a “platform company,” which the Financial Times describes as “companies that expand by continually buying rivals in musty and unloved segments of the market, supposedly squeezing out efficiencies as they go along.”.
